Panaji Journal

Peritoneal Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Peritoneal Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

November 15
21:25 2022
Peritoneal Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Peritoneal Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Peritoneal Cancer Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Peritoneal Cancer Pipeline Report

  • DelveInsight’s Peritoneal Cancer Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Peritoneal Cancer Companies are working such as Pfizer, ImmunoGen, Boryung Pharmaceutical, OncoQuest, Janssen Research & Development, OncXerna Theraputics, Merck & Co, Sotio a.s., AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Medivation, Inc., Astex Pharmaceuticals, APIM Therapeutics, Celsion, Syndax Pharmaceuticals, ImmunoVaccine Technologies, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, and others
  • Promising Peritoneal Cancer Pipeline therapies such as Mirvetuximab soravtansine, Pembrolizumab, DCVAC/OvCa, PF-06873600, and others
  • The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

 

Recent Developmental Activities in the Peritoneal Cancer Pipeline Report

  • The drug is being investigated in Phase II stage of development for the treatment of Peritoneal Cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer. PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation.
  • SOTIO’s DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique. SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs. It is currently being evaluated in Phase III clinical trial to treat Peritoneal Cancer.
  • Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. Currently it is being evaluated in Phase III stage of development for the treatment of Peritoneal Cancer.
  • Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with Peritoneal Cancer.

 

Request a sample and discover the recent advances in Peritoneal Cancer Medication @ Peritoneal Cancer Treatment Landscape

 

Peritoneal Cancer Overview

The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs. When cancer spreads from other organs, it is considered advanced and denote Stage IV disease in most cases. Complications related to peritoneal metastases include: Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension, Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines, Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect the kidney function. The diagnosis of Peritoneal Cancer can be difficult. Imaging (such as CT or MRI scans), needle drainage of ascitic fluid for analysis, keyhole surgery, or a combination of these may be required to confirm the diagnosis of peritoneal metastases. Treatment of Peritoneal Cancer depends on the stage of cancer, where the primary tumor started, how far it has spread, and the patient’s overall health. Surgery, chemotherapy, radiotherapy, and targeted therapy.

 

Peritoneal Cancer Emerging Drugs

  • Mirvetuximab soravtansine: ImmunoGen
  • Pembrolizumab: Merck & Co
  • DCVAC/OvCa: SOTIO
  • PF-06873600: Pfizer

 

Peritoneal Cancer Pipeline Therapeutics Analysis

There are approx. 50+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

 

Learn more about the emerging Peritoneal Cancer pipeline therapies @ Peritoneal Cancer Clinical Trials

 

Scope of the Peritoneal Cancer Pipeline Report

  • Coverage- Global
  • Peritoneal Cancer Therapeutic Assessment by Product Type
  • Peritoneal Cancer Therapeutic Assessment by Stage and Product Type
  • Peritoneal Cancer Therapeutic Assessment by Route of Administration
  • Peritoneal Cancer Therapeutic Assessment by Stage and Route of Administration
  • Peritoneal Cancer Therapeutic Assessment by Molecule Type
  • Peritoneal Cancer Therapeutic Assessment by Stage and Molecule Type
  • Peritoneal Cancer Companies- Pfizer, ImmunoGen, Boryung Pharmaceutical, OncoQuest, Janssen Research & Development, OncXerna Theraputics, Merck & Co, Sotio a.s., AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Medivation, Inc., Astex Pharmaceuticals, APIM Therapeutics, Celsion, Syndax Pharmaceuticals, ImmunoVaccine Technologies, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, and others
  • Peritoneal Cancer Pipeline therapies- Mirvetuximab soravtansine, Pembrolizumab, DCVAC/OvCa, PF-06873600, and others

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Peritoneal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Mirvetuximab soravtansine: ImmunoGen
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. PF-06873600: Pfizer
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I/II)
  13. ART0380: Artios Pharma
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Peritoneal Cancer Key Companies
  17. Peritoneal Cancer Key Products
  18. Peritoneal Cancer- Unmet Needs
  19. Peritoneal Cancer- Market Drivers and Barriers
  20. Peritoneal Cancer- Future Perspectives and Conclusion
  21. Peritoneal Cancer Analyst Views
  22. Peritoneal Cancer Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Peritoneal Cancer drugs?
  • How many Peritoneal Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peritoneal Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Peritoneal Cancer Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles